Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
playstay77, your PROT call is definitely one for the record books!!!! $4.59 now!!!
EXTO... Buyin it!!! $$$$$
.
SNDY .0010 Major Breakout Coming imo. Load up while you can guys.
Yes indeed!!! Where it will stop... nobody knows!
PROT 3.30! New HOY sick sick sick!
yup... CrAzY man!!!
SNDY .0010 Higher % percentage gainer in volume at PENNY STOCK RUMBLE TODAY. This is ready to explode next week imo!
SNDY .0010's hitting. Slow and steady, This stock hit .02+ last year within days. 10bagger potential in the makings. Breast cancer is a huge market.
SNDY .0008(Solos Endoscopy) Going to be Huge imo. This is my favourite stock of the year. Breast cancer early detection systems are in big demand. The number of women suffering from breast cancer is expected to increase and the need for reliable detection systems is growing. SNDY sales are surging and with the CE mark this stock is ready to go through the roof. Easy .01+ cents potential and news is pending. The last news was end of december so we are due for news this month that will surprise many imo. I think SNDY could go to .02+ to .05 cents with CE mark status imo. Extremely undervalued come check out the SNDY board and get all the DD there.
no fun at all!!!
pneumonia... I don't wish it on anyone!!
.
Oh Hell yea those .32's are loking good. I wish I coulda woulda shoulda!!!
.
Yeah those .32s are looking mighty sweet!
Im glad to hear you are back! not fun being sick:(
DOUBLE WOW!!! ... HUGE CALL playstay77! Congrats BIG MONEY!
I wish I wasnt so sick and I was playing it! But I'm back in action now almost 100%!!
.
PROT Huge news last week. Ran 82% on Friday with monster volume and closed HOY (High of Year) .95!! And it just begun... rumors are circulating that some big things are happening with this little gem. Based off the latest trading, I think we might be seeing them come to fruition.
SHKZ .0022 now I mentioned this on IHUB from .0015 and now its up 40%+ :) Wheee slow and steady she goes. 4th major acquisition+ new website completion+ name/ticker change to reflect RenuEN Corporation ( the new Solar Energy name) + alot of news coming in pipeline one after the other as per IR Micheal Irving. We broke 50 day ma at .0021 and now 200 day ma .0064 is next. We could see .02+ potentially in 2 weeks or less when news is expected... imo this is going to be HUGE! All this in 2 weeks max or less as confirmed by Investor relations :) Okay fine its not a weeks play but just 2 weeks max based on investor relations email and phone call. I think we can make alot more than 2k on this one wouldn't you think so? Happy new years and Good luck to everyone.
been a bit slow lately, but I have a feeling it will be heating up soon in here! $$$$$$$$$$$ :)
.
no one following this board anymore
PROT HUGE 8K out!!
FDA clinical trials at the University of Miami!!
- Current report filing (8-K)
Date : 11/15/2011 @ 1:14PM
Source : Edgar (US Regulatory)
Stock : (PROT)
Quote : 0.53 -0.19 (-26.39%) @ 11:31AM
- Current report filing (8-K)
print
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 15, 2011
Commission File Number: 000-53750
PROTEONOMIX, INC.
(Name of Registrant in Its Charter)
Delaware
13-3842844
(State or Other Jurisdiction of
(I.R.S. Employer Identification No.)
Incorporation or Organization)
187 Mill Lane, Mountainside, New Jersey
07052
(Address of Principal Executive Offices)
(Zip Code)
(973) 544 – 6116
(Issuer ’ s Telephone Number, Including Area Code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 1 – Registrant ’ s Business and Operations
Item 1.01 Entry into a Material Definitive Agreement
On November 15, 2011, Proteonomix, Inc. (the “ Issuer ” ) today entered into an agreement with The University of Miami (the “ University ” ), a premier educational institution, to conduct a FDA human clinical trial, in patients afflicted with End Stage Liver Disease ( “ ESLD ” ), of the Issuer ’ s UMK-121 Biopharmaceutical Stem Cell Technology ( “ UMK-121 ” ) which is a proprietary technology based upon existing FDA approved drugs. The Issuer sublicensed UMK-121 to its wholly owned subsidiary THOR BioPharma. The Issuer is required to pay $105,000 to the University and the University will absorb all other costs associated with the study. The Issuer has agreed to pay a 3% net royalty in the event of commercialization of UMK-121.
Exhibit 10.59 Agreement Between Issuer and The University of Miami dated November 15, 2011.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PROTEONOMIX, INC.
Dated: November 15, 2011
By: /s/Michael Cohen
Name: Michael Cohen
President
All good here my friend. Im looking forward to it.
Hey stranger! How ya been? Yep PROT is just starting to roll. The BIG news has yet hit. When it does, Gonna get real fun:)
Nice... Up .21 today. could be on to something play!
PROT HUGE NEWS!!!
Proteonomix, Inc. (PROT) Announces That Its Subsidiary Proteoderm, Inc. Has Received the Approval of Its Application for INCI...
Date : 11/11/2011 @ 4:00PM
Source : MarketWire
Stock : Proteonomix (PROT)
Quote : 0.51 0.065 (14.61%) @ 4:22PM
Proteonomix, Inc. (PROT) Announces That Its Subsidiary Proteoderm, Inc. Has Received the Approval of Its Application for INCI...
print
Proteonomix (OTCBB:PROT)
Historical Stock Chart
1 Month : October 2011 to November 2011
Click Here for more Proteonomix Charts.
PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the Cosmetic Ingredients Review Board ("CIR") has approved and assigned an INCI nomenclature to its innovative Matrix NC-138 Cosmeceutical product, a necessary final step prior to manufacturing and commercialization of cosmetic products in the United States.
Michael Cohen, President of the Company, stated: "The approval of the CIR and its issuance of an INCI name to our Matrix NC-138 is a significant and momentous occasion. We have now demonstrated that we are committed to develop and deliver to the market safe and innovative products. The issuance of the INCI name will allow the company to move forward with commercialization of our cosmeceutical product, Proteoderm NC-138 in the USA."
Proteoderm Inc. has developed a line of anti-aging skin care cosmetics based on its research with stem cell derivatives. We are the first company to use a matrix of proteins ("Matrix NC-138") originally discovered in non-embryonic stem cells, to harness the anti-aging potential in cosmeceutical products.
Mr. Cohen continued: "We anticipate that our efforts to market the product and partner up with other cosmetic manufacturers will be greatly enhanced by the issuance of an INCI name."
Based in Washington, D.C., the Personal Care Product Council ("PCPC") has funded the Cosmetic Ingredient Review ("CIR") Expert Panel as an independent, nonprofit panel of scientists and physicians established in 1976 to assess the safety of ingredients used in cosmetics in the U.S. with the support of the U.S. Food and Drug Administration and the Consumer Federation of America in an open, unbiased, and expert manner, and to publish the results in the peer-reviewed scientific literature. The CIR mission is to review and assess the safety of ingredients used in cosmetics in an open, unbiased, and expert manner, and to publish the results in the peer-reviewed scientific literature. Upon conclusion of its review the CIR issues an International Nomenclature of Cosmetic Ingredients ("INCI") name to the ingredient. The PCPC does not regulate but provides information on national and international regulation. We presently adhere to the Personal Care Products Council Consumer Commitment Code, including filing timely reports with the FDA regarding manufacturing and ingredient usage.
About Proteonomix, Inc.:
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix Family of companies includes Proteoderm, StromaCel, National Stem Cell, PRTMI and THOR Biopharma. Proteoderm, Inc. is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel, Inc. develops therapeutic modalities for the treatment of Cardiovascular Disease (CVD). National Stem Cell, Inc. is Proteonomix's operating subsidiary. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.otcqb.com/ and http://www.sec.gov/.
Forward-looking statements:
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.
Contact:
Proteonomix, Inc.
Michael Cohen
CEO
Phone: +1-973-544-6116
Email: Email Contact
FPP Hit $2.95 Technical Breakout Today at $2.80 Achieved
What a Great Day in the Market, Now is the time to take another look at AMEX: FPP
Today the stock hit $2.95 which is very bullish on the short term and needs to break though the 200 day moving average of $3.30 for long term bullish buy signal.
Proteonomix, Inc. (PROT) to Move Forward With Offshore Stem Cell Testing
Date : 10/19/2011 @ 4:45PM
Source : MarketWire
Stock : Proteonomix (PROT)
Quote : 0.72 0.07 (10.77%) @ 2:09PM
Proteonomix, Inc. (PROT) to Move Forward With Offshore Stem Cell Testing
print
Proteonomix (OTCBB:PROT)
Intraday Stock Chart
Today : Wednesday 19 October 2011
Click Here for more Proteonomix Charts.
PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it intends to move forward with the testing of its StromaCel technology through its PRTMI subsidiary or its affiliates. The Company decided to examine the possibility of testing its cardiac stem cell treatment offshore in light of the progress toward its trial of UMK-121, its stem cell treatment for patients awaiting liver transplant to overcome End Stage Liver Disease ("ESLD"), in the United States.
Michael Cohen, President of the Company, stated: "Since we progress toward the commencement of our trial of UMK-121 in the United States, we have decided to explore the possible testing of our cardiac treatment offshore in order to reduce the cost of bringing the cardiac treatment to market. This strategic decision is being made in recognition of the increasing costs associated with bringing a new drug to market in the United States through the NDA (New Drug Application) process and the availability of expert medical testing capabilities offshore at a fraction of the cost."
Mr. Cohen continued: "Once we have established the efficacy of our cardiac stem cell treatment offshore and have commenced foreign sales, then we will be in a better financial position to pursue the NDA in the United States." We have been approached by one group that has expressed interest in exploring such a possibility and we will follow through with this in the coming weeks. Meanwhile, we will seek out others interested in a similar transaction keeping in mind at all times that any such deal would have to provide immediate benefit to our shareholders."
About Proteonomix, Inc.:
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix Family of companies includes Proteoderm, StromaCel, National Stem Cell, PRTMI and THOR Biopharma. Proteoderm, Inc. is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel, Inc. develops therapeutic modalities for the treatment of Cardiovascular Disease (CVD). National Stem Cell, Inc. is Proteonomix's operating subsidiary. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.otcqb.com/ and http://www.sec.gov/.
Forward-looking statements:
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.
Contact:
Proteonomix, Inc.
Michael Cohen
CEO
Phone: +1-973-544-6116
Email: Email Contact
PROT its getting ready to go...
LUSI hit .084!! almost 100% from .045!!!
Im hearing a broker is 500k short on LUSI. A short squeeze is imminent, its at the bottom. Some peeps are circling the wagons...
STXS great move so far today on it's way to $2.20 near term imo!!
/
well, we should also mention STXS for this crowd, too. Great idea for this board.
ok, I'm starting to buy AVIX !!!
Hell yea... great call play!
EXTO closed over a penny on HUGE news today Reduction of 71% of AS. Now the real journey begins. Nickel land is on the radar next.
Ok... back in action. Now let's make some $$$$$$$$$
SCFR if everyone gets in on this we could probably see $1
Share Structure
Market Value $26,193,201 a/o Aug 22, 2011
Shares Outstanding 873,106,700 a/o Aug 11, 2011
Float 12,427,440 a/o Aug 11, 2011
Authorized Shares 2,010,000,000 a/o Aug 11, 2011
Par Value Not Available
Recent figures show that sign ups at Free Poker sites often times exceed 1 Million per month, with our New online game we anticipate that figure to generate 13 Million Dollars per month or more in potential revenue in the near future as many states like California and New Jersey are now considering and preparing Bills to introduce for Online Gaming Poker Clubs and Websites.
EXTO hit a penny plus!! Just starting the move into copperland.
EXTO hit 79 so far on the HUGE news out!
http://www.otcmarkets.com/stock/EXTO/news
MASP put it on radar. Insider buying, 21Milly @ .0043
http://ih.advfn.com/p.php?pid=nmona&article=48867690
Followers
|
17
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
287
|
Created
|
11/28/09
|
Type
|
Free
|
Moderators |
$2KAWEEK Theme songs...
http://www.youtube.com/watch?v=di60NYGu03Y
http://www.youtube.com/watch?v=aSvUh5p0ETc
http://www.youtube.com/watch?v=PRUR94yMjew
Welcome to the $2KAWEEK CLUB BOARD!
If you think this board is for you please boardmark it and we will work as a team to accomplish our goal!!
MISSION STATEMENT:
Our goal for 2011 will be to combine the efforts of eveyone so we can all make 2kaweek consistantly.
We're not going to be greedy and try to make a years pay in one day we just want to be consistant and it will be a win-win-win for all of us!
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
I admit the ibox is kind of plain but it's a work in progress. (any creative volunteers)??
I want to make this a FUN place to hang out..... but without loosing focus on our goal.
Ok, now I'm going to find some good plays to make us all some $$$$$$
buythemflipthemmoveonbuythemflipthemmoveonbuythemflipthemmoveonbuythemdonotmarrythemmoveon
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |